AVEO Pharmaceuticals, Inc. (AVEO)

[Biotech Pharmer]

Unfortunately, nano caps that constantly offer up new shares rarely play by the "should be" rules. It topped out at 42.50(split adjusted) in 2017 upon EMA approval. The shares outstanding at the time were 11.83M split adjusted and we now have 16.08M shares out,so it's been diluted 36%. So $42.50 less 36% = $27.20. But that 42.50 reflected the EMA/EUSA deal, which is and has always been just a royalty deal for AVEO. I think FDA acceptance could push this to the $60-$80 range on the pop, consolidating to $40-$50. Of course, this prediction is predicated on future dilution that is going to take place.